333 related articles for article (PubMed ID: 19183887)
1. Toxicity studies of cremophor-free paclitaxel solid dispersion formulated by a supercritical antisolvent process.
Park JH; Chi SC; Lee WS; Lee WM; Koo YB; Yong CS; Choi HG; Woo JS
Arch Pharm Res; 2009 Jan; 32(1):139-48. PubMed ID: 19183887
[TBL] [Abstract][Full Text] [Related]
2. Cremophor-free intravenous microemulsions for paclitaxel I: formulation, cytotoxicity and hemolysis.
Nornoo AO; Osborne DW; Chow DS
Int J Pharm; 2008 Feb; 349(1-2):108-16. PubMed ID: 17869459
[TBL] [Abstract][Full Text] [Related]
3. Antitumor efficacy of solid dispersion of paclitaxel prepared by supercritical antisolvent process in human mammary tumor xenografts.
Shanmugam S; Park JH; Chi SC; Yong CS; Choi HG; Woo JS
Int J Pharm; 2011 Jan; 403(1-2):130-5. PubMed ID: 20974239
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, tissue distribution and anti-tumour efficacy of paclitaxel delivered by polyvinylpyrrolidone solid dispersion.
Liu X; Sun J; Chen X; Wang S; Scott H; Zhang X; Zhang Q
J Pharm Pharmacol; 2012 Jun; 64(6):775-82. PubMed ID: 22571255
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, biodistribution, efficacy and safety of N-octyl-O-sulfate chitosan micelles loaded with paclitaxel.
Zhang C; Qu G; Sun Y; Wu X; Yao Z; Guo Q; Ding Q; Yuan S; Shen Z; Ping Q; Zhou H
Biomaterials; 2008 Mar; 29(9):1233-41. PubMed ID: 18093646
[TBL] [Abstract][Full Text] [Related]
6. Preparation and evaluation of Cremophor-free paclitaxel solid dispersion by a supercritical antisolvent process.
Park JH; Yan YD; Chi SC; Hwang DH; Shanmugam S; Lyoo WS; Woo JS; Yong CS; Choi HG
J Pharm Pharmacol; 2011 Apr; 63(4):491-9. PubMed ID: 21401600
[TBL] [Abstract][Full Text] [Related]
7. Novel self-assembling PEG-p-(CL-co-TMC) polymeric micelles as safe and effective delivery system for paclitaxel.
Danhier F; Magotteaux N; Ucakar B; Lecouturier N; Brewster M; Préat V
Eur J Pharm Biopharm; 2009 Oct; 73(2):230-8. PubMed ID: 19577643
[TBL] [Abstract][Full Text] [Related]
8. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol).
Sparreboom A; Scripture CD; Trieu V; Williams PJ; De T; Yang A; Beals B; Figg WD; Hawkins M; Desai N
Clin Cancer Res; 2005 Jun; 11(11):4136-43. PubMed ID: 15930349
[TBL] [Abstract][Full Text] [Related]
9. Cremophor-free intravenous microemulsions for paclitaxel II. Stability, in vitro release and pharmacokinetics.
Nornoo AO; Chow DS
Int J Pharm; 2008 Feb; 349(1-2):117-23. PubMed ID: 17869458
[TBL] [Abstract][Full Text] [Related]
10. Physicochemical stability, pharmacokinetic, and biodistribution evaluation of paclitaxel solid dispersion prepared using supercritical antisolvent process.
Shanmugam S; Park JH; Chi SC; Yong CS; Choi HG; Woo JS
Drug Dev Ind Pharm; 2011 Jun; 37(6):628-37. PubMed ID: 21401339
[TBL] [Abstract][Full Text] [Related]
11. Novel biocompatible intraperitoneal drug delivery system increases tolerability and therapeutic efficacy of paclitaxel in a human ovarian cancer xenograft model.
Vassileva V; Grant J; De Souza R; Allen C; Piquette-Miller M
Cancer Chemother Pharmacol; 2007 Nov; 60(6):907-14. PubMed ID: 17375303
[TBL] [Abstract][Full Text] [Related]
12. Intravenous administration of paclitaxel in Sprague-Dawley rats: what is a safe dose?
Shord SS; Camp JR
Biopharm Drug Dispos; 2006 May; 27(4):191-6. PubMed ID: 16566060
[TBL] [Abstract][Full Text] [Related]
13. Enhanced absorption and tissue distribution of paclitaxel following oral administration of DHP 107, a novel mucoadhesive lipid dosage form.
Shin BS; Kim HJ; Hong SH; Lee JB; Hwang SW; Lee MH; Yoo SD
Cancer Chemother Pharmacol; 2009 Jun; 64(1):87-94. PubMed ID: 18941747
[TBL] [Abstract][Full Text] [Related]
14. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL.
Sparreboom A; van Tellingen O; Nooijen WJ; Beijnen JH
Cancer Res; 1996 May; 56(9):2112-5. PubMed ID: 8616858
[TBL] [Abstract][Full Text] [Related]
15. Preliminary in vivo studies of a new lecithin-based formulation of paclitaxel.
Sznitowska M; Bodnar M; Petrusewicz J; Janik H; Dabrowska EA
J Microencapsul; 2009 Nov; 26(7):588-92. PubMed ID: 19839794
[TBL] [Abstract][Full Text] [Related]
16. Thermoreversible liposomal poloxamer gel for the delivery of paclitaxel: dose proportionality and hematological toxicity studies.
Dhanikula RS; Dhanikula AB; Panchagnula R
Pharmazie; 2008 Jun; 63(6):439-45. PubMed ID: 18604987
[TBL] [Abstract][Full Text] [Related]
17. Novel Taxol formulation: polyvinylpyrrolidone nanoparticle-encapsulated Taxol for drug delivery in cancer therapy.
Sharma D; Chelvi TP; Kaur J; Chakravorty K; De TK; Maitra A; Ralhan R
Oncol Res; 1996; 8(7-8):281-6. PubMed ID: 8938791
[TBL] [Abstract][Full Text] [Related]
18. Multiple-pool cell lifespan models for neutropenia to assess the population pharmacodynamics of unbound paclitaxel from two formulations in cancer patients.
Bulitta JB; Zhao P; Arnold RD; Kessler DR; Daifuku R; Pratt J; Luciano G; Hanauske AR; Gelderblom H; Awada A; Jusko WJ
Cancer Chemother Pharmacol; 2009 May; 63(6):1035-48. PubMed ID: 18791717
[TBL] [Abstract][Full Text] [Related]
19. Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients.
Bulitta JB; Zhao P; Arnold RD; Kessler DR; Daifuku R; Pratt J; Luciano G; Hanauske AR; Gelderblom H; Awada A; Jusko WJ
Cancer Chemother Pharmacol; 2009 May; 63(6):1049-63. PubMed ID: 18791718
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of paclitaxel-2'-glycinate conjugated to poly(ethylene glycol): a water-soluble prodrug.
Pendri A; Conover CD; Greenwald RB
Anticancer Drug Des; 1998 Jul; 13(5):387-95. PubMed ID: 9702205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
